Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  British Journal of Haematology

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2006.06366.xPMID 17107348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoietin—A Hematopoietic Hormone with Emerging Diverse Activities

  2006cited by this paper
• Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma

  2005cited by this paper
• ERYTHROPOIETIN AS AN IMMUNOTHERAPEUTIC AGENT: NEW USES FOR AN OLD DRUG?

  2005cited by this paper
• High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma

  2005cited by this paper
• Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.

  2005cited by this paper
• Erythropoietin Induced Tumour Mass Reduction in Murine Lymphoproliferative Models

  2005cited by this paper
• Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway

  2005cited by this paper
• A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.

  2005cited by this paper
• Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients.

  2005influential reference
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• Emerging biological roles for erythropoietin in the nervous system

  2005cited by this paper
• Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?

  2004cited by this paper
• Signalling molecules and cytokine production in T cells of multiple myeloma‐increased abnormalities with advancing stage

  2004cited by this paper
• Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin.

  2004cited by this paper
• Erythropoietin has an anti‐myeloma effect – a hypothesis based on a clinical observation supported by animal studies

  2004cited by this paper
• Anemia in multiple myeloma.

  2004cited by this paper
• Erythropoietin as a novel neuroprotectant

  2004cited by this paper
• Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival.

  2003cited by this paper
• The implications of anemia in multiple myeloma.

  2003cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

  2003cited by this paper
• The Effect of Erythropoietin Therapy and Hemoglobin Levels on the Immune Response to Engerix-B Vaccination in Chronic Kidney Disease

  2003cited by this paper
• A novel role for erythropoietin during fibrin-induced wound-healing response.

  2003cited by this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• Neuroprotective properties of epoetin alfa.

  2002cited by this paper
• Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16.

  2002cited by this paper
• New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI.

  2002cited by this paper
• Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients.

  2002influential reference
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.

  2002cited by this paper
• The Polymorphonuclear Leukocyte – A New Target for Erythropoietin

  2001cited by this paper
• Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

  2001cited by this paper
• Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients.

  2000cited by this paper
• Multiple myeloma.

  2000cited by this paper
• Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients.

  1999cited by this paper
• Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment.

  1998cited by this paper
• Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking.

  1998cited by this paper
• Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot

  1998cited by this paper
• The expression of T cell related costimulatory molecules in multiple myeloma.

  1998cited by this paper
• CD4+ T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers.

  1998cited by this paper
• The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients.

  1998cited by this paper
• CD8+ T‐cell clones in old mice

  1997cited by this paper
• Immunoregulatory mechanisms in multiple myeloma.

  1997cited by this paper
• Bone marrow T-cell subsets in patients with monoclonal gammopathies: correlation with clinical stage and disease status.

  1997cited by this paper
• T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden

  1997cited by this paper
• Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.

  1997cited by this paper
• Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients.

  1996cited by this paper
• Duration of TCR stimulation determines costimulatory requirement of T cells.

  1996cited by this paper
• The effect of erythropoietin administration on murine bone marrow chimeras.

  1996cited by this paper
• Stimulation of Interleukin-1 ß Production may be Involved in Unresponsiveness to Erythropoietin Therapy

  1996cited by this paper
• Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation

  1996cited by this paper
• Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients.

  1996cited by this paper
• Immunophenotype and DNA cell content in multiple myeloma.

  1995cited by this paper
• Multiple myeloma: current treatment.

  1994cited by this paper
• Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells.

  1994cited by this paper
• Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors.

  1994cited by this paper
• Recombinant human erythropoietin and the anemia of cancer.

  1994cited by this paper
• Recombinant human erythropoietin increases interleukin-1 beta production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy.

  1994cited by this paper
• Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes

  1992cited by this paper
• Improved Immunoglobulin Production in Dialysis Patients Treated with Recombinant Erythropoietin

  1992cited by this paper
• T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment.

  1992cited by this paper
• Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum‐free medium

  1991cited by this paper
• Erythropoietin.

  1991cited by this paper
• Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients.

  1991cited by this paper
• Expression of the erythropoietin receptor on a human myeloma cell line.

  1990cited by this paper
• Multiple myeloma: altered CD4/CD8 ratio in bone marrow.

  1990cited by this paper
• [Erythropoietin treatment of tumor-associated anemia in patients with multiple myeloma].

  1990cited by this paper
• Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.

  1989cited by this paper
• T‐cells of multiple myeloma patients triggered by the autologous mixed lymphocyte reaction suppress polyclonal immunoglobulin synthesis

  1988cited by this paper
• Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin.

  1988cited by this paper
• Abnormal clonogenic potential of T cells from multiple myeloma patients.

  1985cited by this paper
• Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels.

  1985cited by this paper
• Immunoregulatory circuits in myeloma.

  1982cited by this paper
• Immunoregulatory T cell function in multiple myeloma.

  1981cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Erythropoietin-Mediated Secretion of Transforming Growth Factor β1 by Bone Marrow Mononuclear Cells is Negatively Regulated by Granulocytes via Secretion of Erythropoietin Receptors in the Milieu.

  2021cites this paper
• Granulocytes Negatively Regulate Secretion of Transforming Growth Factor β1 by Bone Marrow Mononuclear Cells via Secretion of Erythropoietin Receptors in the Milieu

  2021cites this paper
• Erythrotropin for Treating Anemia in Multiple Myeloma: Response to Treatment and Survival

  2020cites this paper
• Erythropoietin Treatment Is Associated with Decreased Blood Glucose Levels in Hematologic Patients

  2020cites this paper
• About The Interconnection Between Erythropoietin, Mononuclears And Colon Carcinoma Cells

  2018cites this paper
• Erythropoietin enhances Kupffer cell number and activity in the challenged liver

  2017cites this paper
• Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.

  2017cites this paper
• Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro

  2016cites this paper
• rythropoietin administration is associated with improved T-cell roperties in patients with myelodysplastic syndromes

  2016cites this paper
• Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss

  2016cites this paper
• Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation

  2015cites this paper
• Discovery And Validation Of Early Life Plasma Protein Biomarkers For Childhood Asthma

  2014cites this paper
• Does erythropoietin have a role in the treatment of β-hemoglobinopathies?

  2014cites this paper
• Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma

  2013cites this paper
• Erythropoietin Protects against Murine Cerebral Malaria through Actions on Host Cellular Immunity

  2013cites this paper
• Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.

  2013cites this paper
• Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients.

  2013cites this paper
• Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta

  2012cites this paper
• AZA-ESA combo: a new standard for higher risk MDS?

  2012cites this paper
• Study of Erythropoeitin on IGM serum levels in HCV positive patients on regular HD

  2012cites this paper
• Study of ERYTHROPOEITIN Effect ON IgM serum levels IN HCV positive patients on regular HD

  2012cites this paper
• Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.

  2012cites this paper
• Erythropoietin enhances immunostimulatory properties of immature dendritic cells

  2011cites this paper
• Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes (reply)

  2011cites this paper
• Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes

  2011cites this paper
• Immune alterations in untreated and treated myelodysplastic syndrome

  2011cites this paper
• Cytokines in MDS: Abnormalities and Treatment

  2011cites this paper
• Macrophages as novel targets for erythropoietin

  2010cites this paper
• Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver.

  2010cites this paper
• Bench to bedside: A role for erythropoietin in sepsis

  2010cites this paper
• Autoimmune lymphoproliferative syndrome: a multifactorial disorder

  2010cites this paper
• Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches

  2010cites this paper
• Macrophages as novel target cells for erythropoietin

  2010cites this paper
• The lower risk MDS patient at risk of rapid progression.

  2010cites this paper
• Non-erythroid effects of erythropoietin

  2010cites this paper
• Biological functions and therapeutic use of erythropoiesis‐stimulating agents: perplexities and perspectives

  2009cites this paper
• Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells.

  2009influential citation
• Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models.

  2009cites this paper
• Non-erythroid effects of erythropoietin: are neutrophils a target?

  2009cites this paper
• Erythropoietin and Cyclophosphamide Combination Treatment Additively Enhances Antibody Production in Mice

  2009cites this paper
• on-erythroid activities of erythropoietin : Functional effects on urine dendritic cells

  2009cites this paper
• Impact of anemia and red blood cell transfusion on organ function

  2008cites this paper
• Pathophysiology of anemia in cancer

  2008cites this paper
• Anemia and Erythropoeitic Growth Factors in Multiple Myeloma

  2008cites this paper
• Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?

  2008cites this paper
• Prospects and perils of retrospective risk assessment of erythropoiesis‐stimulating agents

  2008cites this paper
• Role of Erythropoietin in Cancer-related Anaemia: A Double-edged Sword?

  2008cites this paper
• The role of recombinant erythropoietin in childhood cancer.

  2008cites this paper
• The non‐haematopoietic biological effects of erythropoietin

  2008cites this paper
• Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?

  2008influential citation
• Erythropoietin enhances immune responses in mice

  2007cites this paper
• Immunodeficiency and immunotherapy in multiple myeloma

  2007cites this paper
• Leukemias and plasma cell dyscrasias

  2007cites this paper
• Immunological and Clinical Long-Term Effects of Idiotype Vaccination in Multiple Myeloma Patients

  2007cites this paper
• Wpływ leczenia rekombinowaną ludzką erytropoetyną (rnEPO) na dynamikę aktywacji i proliferacji limfocytów T CD4+ u chorych hemodializowanych i przewidzianych do przeszczepu nerki

  2007cites this paper
• Immune reconstitution after autologous hematopoietic stem cell transplantation

  2007cites this paper
• Multiple Myeloma: Charging Toward a Bright Future

  2007cites this paper
• Activities of erythropoietin on tumors: An immunological perspective

  2007cites this paper